A COMPETITIVE RECEPTOR-BINDING ASSAY FOR PLATELET-ACTIVATING-FACTOR (PAF) - QUANTIFICATION OF PAF IN RAT-BRAIN

被引:0
作者
TIBERGHIEN, C [1 ]
LAURENT, L [1 ]
JUNIER, MP [1 ]
DRAY, F [1 ]
机构
[1] INST PASTEUR,INSERM,U207,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE
来源
JOURNAL OF LIPID MEDIATORS | 1991年 / 3卷 / 03期
关键词
PLATELET-ACTIVATING FACTOR; RADIORECEPTOR BINDING ASSAY; RAT BRAIN; LYSO-PAF;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A radioreceptor assay (RRA) was developed using rabbit platelet membrane preparations to quantify platelet-activating factor (PAF) and lyso-PAF, the deacetylated derivative of PAF, in a variety of tissues and biological fluids. We examined PAF and lyso-PAF levels in different rat brain areas with regard to the many proven and postulated actions of PAF in brain functions. Human saliva was selected to check the validity of this RRA. The samples were extracted with methanol/chloroform/water and purified by high-performance liquid chromatography on a 5-mu-m Nucleosil Si column (overall recovery: 78%). Sample extracts were acetylated before chromatography to assay lyso-PAF. PAF itself was assayed in non-acetylated samples. A competitive binding assay was performed using aliquots of platelet membrane preparation and tritiated PAF. The minimum detectable amount of PAF was 144 pg per tube and the receptor was highly specific for PAF. In human saliva, we confirm the presence of PAF and lyso-PAF within the range expected. Moreover there was a good correlation between the RRA and the aggregation assay (r = 0.976). A defined cocktail of protease inhibitors allowed storage of platelet membrane preparations for at least 3 months at -20-degrees-C with no change in binding properties. In the brain we observed the prevalent presence of lyso-PAF and large variations in PAF and lyso-PAF concentrations between the different brain areas analyzed. PAF was undetectable in the hypothalamus but the lyso-PAF concentration was 2.5-mu-g/g wet tissue. The PAF concentration in the cortex varied from 0 to 16 ng/g wet tissue while that of lyso-PAF was 0.7-mu-g/g wet tissue. Moreover the amount of lyso-PAF varied between the different brain areas analyzed. The hippocampus contained the highest amount (7-mu-g/g wet tissue), and relatively high levels were found in the hypothalamus, medulla oblongata and corpus striatum. The cerebellum and cortex contained the lowest levels of lyso-PAF. These findings show that PAF is present in the central nervous system mainly in its inactive form, lyso-PAF, and suggest that its effects as a modulator of brain function may be dependent on deacetylation, rather than synthesis.
引用
收藏
页码:249 / 266
页数:18
相关论文
共 50 条
[21]   ALBUMIN INHIBITS PLATELET-ACTIVATING-FACTOR (PAF)-INDUCED RESPONSES IN PLATELETS AND MACROPHAGES - IMPLICATIONS FOR THE BIOLOGICALLY-ACTIVE FORM OF PAF [J].
GRIGORIADIS, G ;
STEWART, AG .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (01) :73-77
[22]   STRUCTURE-ACTIVITY-RELATIONSHIPS FOR PLATELET-ACTIVATING-FACTOR (PAF) AND ANALOGS REVEAL DIFFERENCES BETWEEN PAF RECEPTORS ON PLATELETS AND MACROPHAGES [J].
STEWART, AG ;
GRIGORIADIS, G .
JOURNAL OF LIPID MEDIATORS, 1991, 4 (03) :299-308
[23]   THE LYSO-PRECURSOR OF PLATELET-ACTIVATING-FACTOR (LYSO-PAF) IN ISCHEMIC MYOCARDIUM [J].
LEONG, L ;
STURM, M ;
TAYLOR, R .
JOURNAL OF LIPID MEDIATORS, 1991, 4 (03) :277-287
[24]   PATHOPHYSIOLOGY OF ACUTE-PANCREATITIS - THE ROLE OF PLATELET-ACTIVATING-FACTOR (PAF-ACETHER) [J].
AIS, JG ;
NOVO, C ;
GOMEZGARRE, M ;
LOPEZFARRE, A ;
LOPEZNOVOA, JM ;
ROMEO, JM .
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1992, 81 (01) :25-28
[25]   Role of platelet-activating-factor (PAF) on cellular responses after stimulation with leptospire lipopolysaccharide [J].
Isogai, E ;
Hirose, K ;
Kimura, K ;
Hayashi, S ;
Kubota, T ;
Fujii, N ;
Isogai, H .
MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (03) :271-275
[26]   A NOVEL CLASS OF PLATELET-ACTIVATING-FACTOR (PAF) ANTAGONISTS .1. SYNTHESIS AND STRUCTURE ACTIVITY STUDIES ON PAF-SULFONAMIDE ISOSTERES [J].
TSURI, T ;
HAGA, N ;
MATSUI, T ;
KAMATA, S ;
KAKUSHI, H ;
UCHIDA, K .
CHEMICAL & PHARMACEUTICAL BULLETIN, 1992, 40 (01) :75-84
[27]   RELEASE OF PLATELET-ACTIVATING-FACTOR (PAF) AND EICOSANOIDS IN UVC-IRRADIATED CORNEAL STROMAL CELLS [J].
SHENG, YH ;
BIRKLE, DL .
CURRENT EYE RESEARCH, 1995, 14 (05) :341-347
[28]   SIGNIFICANCE AND REGULATION OF GASTRIC-SECRETION OF PLATELET-ACTIVATING-FACTOR (PAF-ACETHER) IN MAN [J].
SOBHANI, I ;
DENIZOT, Y ;
VISSUZAINE, C ;
VATIER, J ;
BENVENISTE, J ;
LEWIN, MJM ;
MIGNON, M .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (10) :1583-1592
[29]   PLATELET RESPONSE TO THE AGGREGATORY EFFECT OF PLATELET-ACTIVATING-FACTOR (PAF) EXVIVO IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION [J].
TSELEPIS, AD ;
TSOUKATOS, D ;
DROUDES, C ;
DONAS, A ;
EVANGELOU, A .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (05) :490-496
[30]   MENINGOCORTICAL LESION INCREASES EXPRESSION OF THE CHOLECYSTOKININ GENE IN RAT CEREBRAL-CORTEX - EVIDENCE FOR THE INVOLVEMENT OF PLATELET-ACTIVATING-FACTOR (PAF) [J].
GOTZ, E ;
OLENIK, C ;
UHL, A ;
SEREGI, A ;
MEYER, DK .
MOLECULAR BRAIN RESEARCH, 1993, 18 (04) :285-289